Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 229,617 Recursion Pharmaceuticals, Inc. $RXRX

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 229,617 shares of the company’s stock, valued at approximately $1,121,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.05% of Recursion Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC increased its holdings in Recursion Pharmaceuticals by 75.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 19,096 shares of the company’s stock valued at $100,000 after acquiring an additional 8,186 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 1,505.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 61,258 shares of the company’s stock worth $299,000 after purchasing an additional 57,443 shares in the last quarter. JTC Employer Solutions Trustee Ltd raised its position in shares of Recursion Pharmaceuticals by 498.5% during the 3rd quarter. JTC Employer Solutions Trustee Ltd now owns 14,317 shares of the company’s stock worth $70,000 after purchasing an additional 11,925 shares during the last quarter. KLP Kapitalforvaltning AS raised its position in shares of Recursion Pharmaceuticals by 19.3% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 73,000 shares of the company’s stock worth $356,000 after purchasing an additional 11,800 shares during the last quarter. Finally, Ascent Wealth Partners LLC lifted its stake in Recursion Pharmaceuticals by 24.4% in the 3rd quarter. Ascent Wealth Partners LLC now owns 21,771 shares of the company’s stock valued at $106,000 after buying an additional 4,275 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on RXRX. UBS Group set a $11.00 price target on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $4.19 on Friday. The business’s 50-day moving average price is $4.50 and its 200 day moving average price is $4.99. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a market capitalization of $2.18 billion, a PE ratio of -2.33 and a beta of 0.95.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $19.36 million. During the same quarter in the prior year, the company posted ($0.34) EPS. The company’s quarterly revenue was down 80.1% compared to the same quarter last year. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Najat Khan sold 124,403 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total transaction of $548,617.23. Following the completion of the sale, the insider directly owned 611,135 shares of the company’s stock, valued at $2,695,105.35. The trade was a 16.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 220,000 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $4.36, for a total value of $959,200.00. Following the completion of the transaction, the director directly owned 6,649,863 shares in the company, valued at $28,993,402.68. This trade represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 585,786 shares of company stock valued at $2,558,598 over the last quarter. Company insiders own 8.43% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.